Data from historic Phase IIb clinical trial for TB vaccine candidate MVA85A published in The Lancet

Vaccine candidate was generally well tolerated, meeting the study’s primary objective of safety; Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.